Sort   by:  
 Page size 
UnknownTowards cascading genetic risk in Alzheimer's disease.
Alzheimer's disease typically progresses in stages, which have been defined by the presence of disease-specific biomarkers: amyloid (A), tau (T) and neurodegeneration (N). This progression of biomarkers has been condensed into the ATN framework, in which each of the biomarkers can be either positive...
S-EPMC11292901 | biostudies-literature
UnknownEnhancing cognitive performance prediction by white matter hyperintensity connectivity assessment.
White matter hyperintensities of presumed vascular origin (WMH) are associated with cognitive impairment and are a key imaging marker in evaluating brain health. However, WMH volume alone does not fully account for the extent of cognitive deficits and the mechanisms linking WMH to these deficits rem...
S-EPMC11629703 | biostudies-literature
UnknownRepurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results.

Background

World Health Organization expert groups recommended mortality trials of four repurposed antiviral drugs - remdesivir, hydroxychloroquine, lopinavir, and interferon beta-1a - in patients hospitalized with coronavirus disease 2019 (Covid-19).

Methods

We randomly assigned inpa...
S-EPMC7727327 | biostudies-literature
UnknownAnalysis of Long-term Follow-up of a Randomized Clinical Trial With Departures From Assigned Treatments: Estimation of Metformin Effects on Diabetes and Its Complications in the Diabetes Prevention Program Outcomes Study.
The Diabetes Prevention Program (DPP) was a 3-year randomized clinical trial (RCT) with evaluation of lifestyle and metformin interventions compared with placebo for diabetes prevention in high-risk adults. Both interventions significantly reduced diabetes incidence, prompting the long-term Diabetes...
S-EPMC12451852 | biostudies-literature
UnknownMutual learning for joint disease detection and severity prediction reveals multimodal pathogenesis for neurodegenerative disorders.

Motivation

Neurodegenerative disorders influence millions of people worldwide, and uncovering the pathogenesis is of urgent need. Many efforts have been made to detect or predict neurodegenerative disorders, while exploring the pathogenesis has been ignored from a systemic perspective.

Re...

S-EPMC12758602 | biostudies-literature
UnknownOverall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer.

Background

The randomized, double-blind OlympiA trial compared 1 year of the oral poly(adenosine diphosphate-ribose) polymerase inhibitor, olaparib, to matching placebo as adjuvant therapy for patients with pathogenic or likely pathogenic variants in germline BRCA1 or BRCA2 (gBRCA1/2pv) and ...
S-EPMC10207856 | biostudies-literature
UnknownNeuropsychiatric symptoms in cognitive decline and Alzheimer's disease: biomarker discovery using plasma proteomics.

Background and objectives

Neuropsychiatric symptoms (NPS) are common in older people with cognitive impairment and Alzheimer's disease (AD). No biomarkers to detect the related pathology or predict the clinical evolution of NPS are available yet. This study aimed to identify plasma proteins ...
S-EPMC12015082 | biostudies-literature
UnknownDeep learning enhanced ALPS reveals genetic and environmental factors of brain glymphatic function.

Background

The glymphatic system plays a critical role in brain waste clearance and health. Diffusion tensor imaging along the perivascular space (DTI-ALPS) is an emerging approach to assess glymphatic function, but manual analysis is limited by its subjectivity and laboriousness in clinical...
S-EPMC12878677 | biostudies-literature
UnknownErtugliflozin and Slope of Chronic eGFR: Prespecified Analyses from the Randomized VERTIS CV Trial.

Background and objectives

A reduction in the rate of eGFR decline, with preservation of ≥0.75 ml/min per 1.73 m2 per year, has been proposed as a surrogate for kidney disease progression. We report results from prespecified analyses assessing effects of ertugliflozin versus placeb...
S-EPMC8729577 | biostudies-literature
UnknownOutcomes of eyes with lesions composed of >50% blood in the Comparison of Age-related Macular Degeneration Treatments Trials (CATT).

Objective

To compare baseline characteristics, treatment frequency, visual acuity (VA), and morphologic outcomes of eyes with >50% of the lesion composed of blood (B50 group) versus all other eyes (Other group) enrolled in the Comparison of Age-Related Macular Degeneration Treatments Trials ...
S-EPMC4306628 | biostudies-literature
Sort   by:  
 Page size